Testing the Addition of an Anti-Cancer Drug, TRC102, to the Usual Chemotherapy Treatment (Pemetrexed, Cisplatin or Carboplatin) During Radiation Therapy for Stage III Non-Squamous Non-Small Cell Lung Cancer

Recruiting

Phase 2

TRC102 with Pemetrexed, Cisplatin, CarboplatinTesting the Addition of an Anti-Cancer Drug, TRC102, to the Usual Chemotherapy Treatment (Pemetrexed, Cisplatin or Carboplatin) During Radiation Therapy for Stage III Non-Squamous Non-Small Cell Lung Cancer

Sponsor:

National Cancer Institute (NCI)

Code:

NCT05198830

Conditions

Lung Adenocarcinoma

Lung Large Cell Carcinoma

Lung Non-Squamous Non-Small Cell Carcinoma

Stage III Lung Cancer AJCC v8

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Carboplatin

Cisplatin

Computed Tomography

Durvalumab

FDG-Positron Emission Tomography

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-04-19. This information was provided to ClinicalTrials.gov by National Cancer Institute (NCI) on 2025-04-16.